Phaseline

Targets › POLR1A

POLR1A (DNA-directed RNA polymerase I subunit RPA1): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Dec 2026.

Catalytic core component of RNA polymerase I (Pol I), a DNA-dependent RNA polymerase which synthesizes ribosomal RNA precursors using the four ribonucleoside triphosphates as substrates. Transcribes 47S pre-rRNAs from multicopy rRNA gene clusters, giving rise to 5.8S, 18S and 28S ribosomal RNAs. (UniProt, O95602)

Open in Phaseline: the race on POLR1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Pidnarulex
RNA Polymerase I inhibitor
POLR2A, POLR1APhase 1Metastatic Malignant Solid Neoplasm; Metastatic Colorectal Adenocarcinoma; Anatomic Stage III Breast Cancer AJCC v8; Burkitt LymphomaDec 2026
Senhwa BiosciencesCX-5461
POLR2A/POLR1A inhibitor; transcription inhibitor targeting ribosomal RNA synthesis
POLR2A, POLR1APhase 1Advanced Solid TumorMar 2027

Conditions

Metastatic Malignant Solid Neoplasm (1) Metastatic Colorectal Adenocarcinoma (1) Anatomic Stage III Breast Cancer AJCC v8 (1) Burkitt Lymphoma (1) Advanced Solid Tumor (1)

Modalities

mixed (1), small molecule (1)

Companies

National Cancer Institute (NCI) (1) Senhwa Biosciences (1)

Related targets

POLR2A (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.